LifeMD (NASDAQ:LFMD – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.24, reports. LifeMD had a negative return on equity of 686.40% and a negative net margin of 52.55%. The company had revenue of $31.41 million for the quarter, compared to the consensus estimate of $32.19 million. LifeMD updated its Q4 2022 guidance to EPS.
LifeMD Price Performance
Shares of LFMD stock traded up $0.40 during mid-day trading on Friday, hitting $2.48. The stock had a trading volume of 224,011 shares, compared to its average volume of 63,681. LifeMD has a 12-month low of $1.80 and a 12-month high of $5.11. The firm has a market capitalization of $76.76 million, a P/E ratio of -1.39 and a beta of 1.16. The firm’s 50-day moving average is $2.18 and its two-hundred day moving average is $2.27.
Institutional Investors Weigh In On LifeMD
Hedge funds have recently made changes to their positions in the company. B. Riley Financial Inc. lifted its stake in shares of LifeMD by 5.2% during the 1st quarter. B. Riley Financial Inc. now owns 1,200,759 shares of the company’s stock worth $4,239,000 after purchasing an additional 59,658 shares during the last quarter. Royce & Associates LP lifted its stake in shares of LifeMD by 43.9% during the 3rd quarter. Royce & Associates LP now owns 852,544 shares of the company’s stock worth $1,680,000 after purchasing an additional 260,058 shares during the last quarter. Shah Capital Management lifted its stake in shares of LifeMD by 18.1% during the 3rd quarter. Shah Capital Management now owns 409,564 shares of the company’s stock worth $806,000 after purchasing an additional 62,864 shares during the last quarter. Granahan Investment Management LLC lifted its stake in shares of LifeMD by 448.1% during the 1st quarter. Granahan Investment Management LLC now owns 295,747 shares of the company’s stock worth $1,044,000 after purchasing an additional 241,793 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of LifeMD during the 1st quarter worth $519,000. 18.35% of the stock is currently owned by hedge funds and other institutional investors.
LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers.
- Get a free copy of the StockNews.com research report on LifeMD (LFMD)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.